Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hatzl, S; Krause, R; Schilcher, G.
Early Treatment with Sotrovimab for Covid-19.
N Engl J Med. 2022; 386(15): 1480
Doi: 10.1056/NEJMc2201606
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Hatzl Stefan
- Co-Autor*innen der Med Uni Graz
- Krause Robert
- Schilcher Gernot
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To the Editor: Three issues are major drawbacks in the trial conducted by Gupta et al. (Nov. 18 issue)(1) on the administration of the SARS-CoV-2 neutralizing antibody sotrovimab to prevent the progression of Covid-19. First, the definition of "high risk" was based on arbitrary factors, as reflected by the low 29-day case fatality rate in the overall trial population (0.2%; 1 of 583 patients) and the low percentage of patients who were admitted to the intensive care unit (0.9%; 5 patients); these data are not representative of a high-risk population.(2) Second, patients with immunocompromise, who constitute an important high-risk population, . . .
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal, Humanized - therapeutic use
- Antibodies, Neutralizing - administration & dosage
- COVID-19 - drug therapy
- Humans - administration & dosage